Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Abstract Background The human monoclonal antibody belimumab (BEL) has emerged as a promising treatment for systemic lupus erythematosus (SLE), particularly for reducing the need for glucocorticoids and minimizing organ damage. The optimal timing of BEL initiation has been unclear; emerging evidence...

Full description

Saved in:
Bibliographic Details
Main Authors: Kanako Kojima, Kunihiro Ichinose, Masataka Umeda, Toshimasa Shimizu, Shuntaro Sato, Takahisa Suzuki, Yoshikazu Nakashima, Akitomo Okada, Yoshiro Horai, Keita Fujikawa, Toshiyuki Aramaki, Taiichiro Miyashita, Masako Furuyama, Naoki Matsuoka, Atsushi Kawakami
Format: Article
Language:English
Published: BMC 2025-05-01
Series:Arthritis Research & Therapy
Subjects:
Belimumab
Systemic lupus erythematosus
SELENA-SLEDAI
Disease duration
Early intervention
B cell therapy
Online Access:https://doi.org/10.1186/s13075-025-03581-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13075-025-03581-0

Similar Items